FGFR Positive Gastroesophageal Cancer Market

Table of Content

1. Introduction
   • Definition of FGFR Positive Gastroesophageal Cancer Market
   • Scope of the Report
2. Methodology
   • Executive Summary
   • Market Overview
   • Market Definition and Segmentation
3. Market Dynamics
   • Drivers
   • Restraints
   • Opportunities
   • Porter's Five Forces Analysis
   • PESTEL Analysis
4. FGFR Positive Gastroesophageal Cancer Market, Type of FGFR alteration:
   • Amplification
   • Mutation
   • Fusion
5. FGFR Positive Gastroesophageal Cancer Market, Type of therapy:
   • FGFR inhibitors
   • Combination therapies
6. FGFR Positive Gastroesophageal Cancer Market, Diagnostic tests for FGFR alterations:
   • Next-generation sequencing (NGS)
   • Fluorescence in situ hybridization (FISH)
   • Immunohistochemistry (IHC)
   • Polymerase chain reaction (PCR)
7. FGFR Positive Gastroesophageal Cancer Market, By Geography
   • North America
     • United States
     • Canada
   • Europe
     • United Kingdom
     • Germany
     • France
     • Spain
     • Italy
     • Rest of Europe
   • Asia-Pacific
     • China
     • Japan
     • India
     • South Korea
     • Australia
     • Rest of Asia-Pacific
   • Latin America
     • Brazil
     • Mexico
     • Rest of Latin America
   • Middle East & Africa
     • Saudi Arabia
     • United Arab Emirates
     • South Africa
     • Rest of Middle East & Africa
8. Competitive Landscape
9. Company Profiles
   • Novartis AG
     • Company Overview
     • Product Portfolio and Description
     • Key Highlights
     • Financial Overview
   • AstraZeneca PLC
   • Bristol Myers Squibb Company
   • Merck & Co., Inc.
   • Eli Lilly and Company
   • Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson)
   • Roche Holding AG
   • Pfizer Inc.
   • Boehringer Ingelheim International GmbH
   • Daiichi Sankyo Company, Limited
10. Conclusion and Future Outlook
11. Appendix
    • Research Methodology
    • About the Pharmanucleus

12. Disclaimer